Autologous Cell Therapy for Ischemic Heart Failure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for patients with advanced heart failure caused by ischemia.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age greater than 18 but less than 80 years
Prior myocardial infarction
Depressed left ventricular ejection fraction (LVEF) ≤ 35%
NYHA functional classification of II to IV
Not under stable optimal medical management
Cardiac surgery or percutaneous coronary intervention within 3 months
Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or 3 months, in the case of any subsequent MI
Prior cell, gene, or transmyocardial laser revascularization therapy
Ventricular wall thickness in target region ≤ 5 mm
Moderate to severe aortic valve stenosis or mechanical valve replacement
Left ventricular aneurysm or thrombus
Left ventricular dysfunction associated with a reversible cause